American Society of Hematology

Figure 4.

$Figure 4. Overall survival (plot A) and risk of leukemic evolution (plot B) in patients with myelodysplastic syndrome classified according WHO categories. / These survival curves were obtained by applying a Cox proportional hazard regression model with time-dependent covariates on 271 patients followed at the University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, between 1992 and 2004. These patients were evaluable for repeated measures of the variables of interest during their follow-up. According to the model adopted, a patient is classified into a WHO subgroup at the time of diagnosis, and remains in the same group as long as the disease remains stable. As a WHO diagnostic parameter changes, the patient will move from the old to a new WHO category, and will subsequently be followed-up in the latter one.  Abbreviations: RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; MDSdel(5q), myelodysplastic syndrome with deletion 5q; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB-1, refractory anemia with excess blasts, type 1; RAEB-2, refractory anemia with excess blasts, type 2.$

Overall survival (plot A) and risk of leukemic evolution (plot B) in patients with myelodysplastic syndrome classified according WHO categories.

These survival curves were obtained by applying a Cox proportional hazard regression model with time-dependent covariates on 271 patients followed at the University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, between 1992 and 2004. These patients were evaluable for repeated measures of the variables of interest during their follow-up. According to the model adopted, a patient is classified into a WHO subgroup at the time of diagnosis, and remains in the same group as long as the disease remains stable. As a WHO diagnostic parameter changes, the patient will move from the old to a new WHO category, and will subsequently be followed-up in the latter one.  Abbreviations: RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; MDSdel(5q), myelodysplastic syndrome with deletion 5q; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB-1, refractory anemia with excess blasts, type 1; RAEB-2, refractory anemia with excess blasts, type 2.

This Feature Is Available To Subscribers Only